These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 15561777)

  • 1. HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization.
    Dragowska WH; Warburton C; Yapp DT; Minchinton AI; Hu Y; Waterhouse DN; Gelmon K; Skov K; Woo J; Masin D; Huxham LA; Kyle AH; Bally MB
    Mol Cancer Res; 2004 Nov; 2(11):606-19. PubMed ID: 15561777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.
    Klos KS; Wyszomierski SL; Sun M; Tan M; Zhou X; Li P; Yang W; Yin G; Hittelman WN; Yu D
    Cancer Res; 2006 Feb; 66(4):2028-37. PubMed ID: 16489002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia-inducible factor-1alpha is an intrinsic marker for hypoxia in cervical cancer xenografts.
    Vukovic V; Haugland HK; Nicklee T; Morrison AJ; Hedley DW
    Cancer Res; 2001 Oct; 61(20):7394-8. PubMed ID: 11606368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracellular coexpression of epidermal growth factor receptor, Her-2/neu, and p21ras in human breast cancers: evidence for the existence of distinctive patterns of genetic evolution that are common to tumors from different patients.
    Shackney SE; Pollice AA; Smith CA; Janocko LE; Sweeney L; Brown KA; Singh SG; Gu L; Yakulis R; Lucke JF
    Clin Cancer Res; 1998 Apr; 4(4):913-28. PubMed ID: 9563885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A.
    Detwiller KY; Fernando NT; Segal NH; Ryeom SW; D'Amore PA; Yoon SS
    Cancer Res; 2005 Jul; 65(13):5881-9. PubMed ID: 15994966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does endogenous fatty acid metabolism allow cancer cells to sense hypoxia and mediate hypoxic vasodilatation? Characterization of a novel molecular connection between fatty acid synthase (FAS) and hypoxia-inducible factor-1alpha (HIF-1alpha)-related expression of vascular endothelial growth factor (VEGF) in cancer cells overexpressing her-2/neu oncogene.
    Menendez JA; Vellon L; Oza BP; Lupu R
    J Cell Biochem; 2005 Apr; 94(5):857-63. PubMed ID: 15669079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.
    Pegram MD; Finn RS; Arzoo K; Beryt M; Pietras RJ; Slamon DJ
    Oncogene; 1997 Jul; 15(5):537-47. PubMed ID: 9247307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CITED4 inhibits hypoxia-activated transcription in cancer cells, and its cytoplasmic location in breast cancer is associated with elevated expression of tumor cell hypoxia-inducible factor 1alpha.
    Fox SB; Bragança J; Turley H; Campo L; Han C; Gatter KC; Bhattacharya S; Harris AL
    Cancer Res; 2004 Sep; 64(17):6075-81. PubMed ID: 15342390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer.
    Liu M; Howes A; Lesperance J; Stallcup WB; Hauser CA; Kadoya K; Oshima RG; Abraham RT
    Cancer Res; 2005 Jun; 65(12):5325-36. PubMed ID: 15958580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction.
    Warburton C; Dragowska WH; Gelmon K; Chia S; Yan H; Masin D; Denyssevych T; Wallis AE; Bally MB
    Clin Cancer Res; 2004 Apr; 10(7):2512-24. PubMed ID: 15073131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomics of breast cancer: enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors.
    Zhang DH; Tai LK; Wong LL; Sethi SK; Koay ES
    Proteomics; 2005 May; 5(7):1797-805. PubMed ID: 15825149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia-induced epithelial VEGF-C/VEGFR-3 upregulation in carcinoma cell lines.
    Simiantonaki N; Jayasinghe C; Michel-Schmidt R; Peters K; Hermanns MI; Kirkpatrick CJ
    Int J Oncol; 2008 Mar; 32(3):585-92. PubMed ID: 18292935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.
    Massarweh S; Osborne CK; Jiang S; Wakeling AE; Rimawi M; Mohsin SK; Hilsenbeck S; Schiff R
    Cancer Res; 2006 Aug; 66(16):8266-73. PubMed ID: 16912207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of disrupted SOX18 transcription factor function on tumor growth, vascularization, and endothelial development.
    Young N; Hahn CN; Poh A; Dong C; Wilhelm D; Olsson J; Muscat GE; Parsons P; Gamble JR; Koopman P
    J Natl Cancer Inst; 2006 Aug; 98(15):1060-7. PubMed ID: 16882943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain.
    Palmieri D; Bronder JL; Herring JM; Yoneda T; Weil RJ; Stark AM; Kurek R; Vega-Valle E; Feigenbaum L; Halverson D; Vortmeyer AO; Steinberg SM; Aldape K; Steeg PS
    Cancer Res; 2007 May; 67(9):4190-8. PubMed ID: 17483330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of HER-2 in MDA-MB-435/LCC6 Tumours is Associated with Higher Metabolic Activity and Lower Energy Stress.
    Dragowska WH; Ginj M; Kozlowski P; Yung A; Ruth TJ; Adam MJ; Sossi V; Bally MB; Yapp DT
    Sci Rep; 2016 Jan; 6():18537. PubMed ID: 26727049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A noninvasive approach for assessing tumor hypoxia in xenografts: developing a urinary marker for hypoxia.
    Nelson DW; Cao H; Zhu Y; Sunar-Reeder B; Choi CY; Faix JD; Brown JM; Koong AC; Giaccia AJ; Le QT
    Cancer Res; 2005 Jul; 65(14):6151-8. PubMed ID: 16024616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia-inducible factor-1alpha promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts.
    Dang DT; Chen F; Gardner LB; Cummins JM; Rago C; Bunz F; Kantsevoy SV; Dang LH
    Cancer Res; 2006 Feb; 66(3):1684-936. PubMed ID: 16452228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. c-erbB-2 related aggressiveness in breast cancer is hypoxia inducible factor-1alpha dependent.
    Giatromanolaki A; Koukourakis MI; Simopoulos C; Polychronidis A; Gatter KC; Harris AL; Sivridis E
    Clin Cancer Res; 2004 Dec; 10(23):7972-7. PubMed ID: 15585632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1α-mediated VEGF-dependent angiogenesis.
    Raja R; Kale S; Thorat D; Soundararajan G; Lohite K; Mane A; Karnik S; Kundu GC
    Oncogene; 2014 Apr; 33(16):2053-64. PubMed ID: 23728336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.